Myovant Sciences
€0.000000
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
People Also Follow
This list is based on the watchlists of people on Stock Events who follow 71M.MU. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Show more...
CEO
Employees
579
Country
Bermuda
ISIN
BMG637AM1024
Listings
0 Comments
Share your thoughts
FAQ
What is Myovant Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Myovant Sciences stocks are traded under the ticker 71M.MU.
How many employees does Myovant Sciences have?▼
As of July 08, 2026, the company has 579 employees.
In which sector is Myovant Sciences located?▼
Myovant Sciences operates in the Manufacturing sector.
When did Myovant Sciences complete a stock split?▼
Myovant Sciences has not had any recent stock splits.